All In Biotech

Drug Trial Radar · NCT04998396

A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)

A Phase 1/2 Open-Label Study of the Safety and Clinical Activity of Gene Therapy for Canavan Disease Through Administration of an Adeno-Associated Virus (AAV) Serotype 9-Based Recombinant Vector Encoding the Human ASPA Gene

Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

26

Planned (sponsor's estimate)

Start

Sep 8, 2021

Primary completion

Oct 13, 2026

Study completion Oct 8, 2032

Sponsor

Lead sponsor
Aspa TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 30 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.

Conditions

  • Canavan Disease

Interventions

  • AAV9 BBP-812Biological

    Sterile solution for injection for 1-time use via volumetric infusion pump

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Baseline up to Week 52
  2. Change from Baseline to 12 Months Post-Infusion in Urine N-acetylaspartate (NAA) LevelsTime frame: Baseline, Month 12
  3. Change from Baseline to 12 Months Post-Infusion in Central Nervous System (CNS) NAA, as Measured by Magnetic Resonance Spectroscopy (MRS)Time frame: Baseline, Month 12

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California · Recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Massachusetts General Hospital (MGH); Center for Rare Neurological Diseases (CRND)

    Boston, Massachusetts · Recruiting

  • Weill Cornell Medicine; Division of Pediatric Neurology

    New York, New York · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.